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Summary
BACKGROUND AND AIMS: A better understanding of
the relationship of homocysteine with cardiovascular risk
factors is needed. The objectives of this study were to as-
sess the serum level of homocysteine in HIV-infected pa-
tients and to analyse the possible association of increased
levels of the amino acid with cardiovascular risk factors,
demographic and clinical characteristics of participants.
METHODS: Cross-sectional study carried out as a supple-
mentary task to the usual controls necessary in HIV-infec-
ted patients in the outpatient clinic of the Hospital Gen-
eral of Castellon, Spain. For two consecutive visits the
demographic, clinical and HIV-related characteristics and
blood analyses results were obtained for each participant.
Homocysteine serum level was documented and the pos-
sible association of the amino acid with all the other study
variables was assessed with a multiple linear regression
analysis.
RESULTS: A total of 145 patients were included. The
mean homocysteine serum level of all participants was
11.9 ± 5.9 µmol/L. A total of 54 patients (37%) presented
homocysteine serum levels higher than the upper limit of
normal. An association was found between higher homo-
cysteine serum level and the following variables: family
history of early coronary disease (P = 0.027), sexual HIV
risk behaviour (P = 0.016), hepatitis C virus co-infection
(P = 0.002), higher height (P = 0.002), higher diastolic
blood pressure (P = 0.049), lower serum level of folic acid
(P <0.001), and lower serum level of vitamin B12 (P =
<0.001).
CONCLUSION: In the HIV population, increased homo-
cysteine serum level is associated with sexual risk beha-
viour and hepatitis C virus coinfection.
Key words: hepatitis C virus; homocysteine; HIV-infected
patients
Introduction
With the advent of antiretroviral therapy there has been a
spectacular decrease in morbidity and mortality in HIV-
infected individuals [1]. However, parallel to this an in-
creased risk of cardiovascular disease has become evident
in these subjects. Many HIV-infected patients have dyslip-
idaemia, hyperglycaemia and central obesity that may be a
side effect of the antiretroviral medication, an effect of on-
going replication of the virus, or the influence of both [2].
In addition, a high prevalence of smoking and other cardi-
ovascular risk factors has been found in these patients [3,
4]. As a result, cardiovascular disease is being increasingly
reported in HIV-infected subjects, and the magnitude of the
problem is expected to increase dramatically in the years
to come [5]. For this reason, the HIV-infected population is
particularly suitable to carry out studies on the influence of
risk factors in the development of cardiovascular disease.
Homocysteine is an amino acid produced by the catabolism
of methionine. Serum levels of homocysteine are determ-
ined by genetic and nutritional factors. They are increased
by dietary deficiencies of folic acid, vitamin B6, vitamin
B12 and other vitamins and by excessive methionine intake
[6]. Hyperhomocysteinaemia has been considered a poten-
tial risk factor for cardiovascular disease for many years [7,
8], and epidemiological studies have suggested a beneficial
role for homocysteine lowering strategies [9]. However, re-
cent large randomised clinical trials have failed to demon-
strate a clear effect of such strategies on clinical outcome
in patients with atherosclerosis [10–13]. As a consequence
the role of the substance as a cardiovascular risk factor has
been seriously questioned [14]. Therefore, a better under-
standing of the true relationship of homocysteine with car-
diovascular risk factors is needed.
In this study, carried out in HIV-infected subjects, the ob-
jectives were to assess serum levels of homocysteine, and
to analyse the possible association of increased levels of the
amino acid with cardiovascular risk factors and the demo-
graphic and clinical characteristics of patients.
Method
Study design and patients
We conducted this cross-sectional study from September
2007 until July 2008 in the HIV outpatient clinic of the
Hospital General of Castellon, University of Valencia in
Spain. The institution provides free of charge comprehens-
ive medical care to HIV-infected people. We enrolled pa-
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tients older than 18 years of age. We excluded pregnant wo-
men, patients with creatinine serum levels >2 mg/dl, and
subjects who were taking vitamin supplements since all of
these circumstances have been demonstrated to influence
homocysteine serum levels [6, 14, 15]. Informed consent
was obtained from every participant.
Procedure and variables included
This study was designed as a supplementary task to the
usual controls required in HIV-infected patients. According
to guidelines [16], these subjects must be monitored every
three to six months in terms of clinical, immunological and
virological status, and receive antiretroviral treatment and
prophylaxis against Pneumocystis jiroveci pneumonia with
trimethoprim/sulfamethoxazole when indicated. The study
was completed at two consecutive visits in every patient.
All patients were seen at both visits by one of the authors.
In the first visit demographic, clinical and HIV-related
characteristics were obtained from each participant (table
1). At the second visit the results of blood analyses taken
after overnight fasting two to four weeks before this visit
were reviewed (table 2). Blood samples were collected
from patients into gel-separator tubes and centrifuged 5 to
15 minutes later. Serum level of homocysteine was meas-
ured with a chemiluminescence immunoassay (Immulite
2500, normal value: 5 to 12 µmol/L, coefficient of variation
of 8%). All the laboratory measurements were conducted
by investigators who were blinded to the characteristics of
the patients.
Statistics
Statistical analysis was performed using Minitab 15 (Min-
itab, Inc.). Continuous variables were summarised as mean
and standard deviation and discrete variables were sum-
marised as percentages. Data were normalised by log trans-
formation for the following variables not showing a normal
distribution: homocysteine, glucose, triglyceride, glyc-
osylated haemoglobin and C-reactive protein serum levels.
To estimate the relationship between homocysteine serum
levels of all patients and all the other study variables, we
carried out a multiple linear regression analysis, using a
best subsets procedure to find the best model. Previously
we eliminated variables that showed no relationship at all
with homocysteine and variables, other than homocysteine,
that were highly correlated with other included variables
to avoid multi-colinearity. For this purpose we used scatter
plots and the Pearson correlation test or the Student t test,
as appropriate. For bivariate analyses we used the follow-
ing tests: chi square test (χ²) for discrete variables, inde-
pendent samples Student's t-tests for normally distributed
continuous variables and Mann-Whitney U test, Wilcoxon
signed ranks test or Kruskal-Wallis H test for non-normally
distributed continuous variables.
A significance level of P = 0.05 was used in all analyses of
the study.
Table 1: Demographical and clinical characteristics of the study patients.
Age, years, mean (± SD) 41.1 (± 8.1)
Gender, patients (%)
– male
– female
103 (71)
42 (29)
Antiretroviral treatment, patients (%)
– protease inhibitor based
– non-protease inhibitor based therapy
– none
52 (36)
65 (45)
28 (19)
History, patients (%)
– diabetes mellitus
– hypertension
– dyslipidaemia
– cardiovascular disease
24 (17)
17 (12)
23 (16)
3 (2)
Family history of early coronary disease *, patients (%) 26 (18)
Current smoker, patients (%) 107 (74)
Alcohol abuse **, patients (%) 32 (22)
HIV risk behaviour, patients (%)
– parenteral
– sexual
82 (57)
63 (43)
Hepatitis C virus co-infection ***, patients (%) 89 (61)
Height (cm), mean (± SD) 169.8 (± 8.8)
Weight (kg), mean (± SD) 68.7 (± 13.5)
Body mass index (kg/m2), mean (± SD) 23.8 (± 4.3)
Waist circumference (cm), mean (± SD) 87.3 (± 11.5)
Hip circumference (cm), mean (± SD) 95.4 (± 9.6)
Waist to hip ratio, mean (± SD) 0.92 (± 0.08)
Blood pressure (mm Hg), mean (± SD)
systolic
diastolic
127.0 (± 19.2)
78.0 (± 13.2)
“HeartScore” **** ≥1%, patients (%) 56 (39)
SD indicates standard deviation; * coronary heart disease in first-degree relatives, male <55 years and female <65 years; ** ten or more alcoholic beverages per week; ***
hepatitis C virus infection diagnosed on serology; **** 10-year risk of suffering a cardiovascular disease calculated at www.heartscore.org/es/Pages/welcome.aspx
according to the 2007 European Guidelines on Cardiovascular Disease Prevention for Spanish patients [N].
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Results
General data
A total of 145 patients were included in the study. 139
(96%) were natives of Spain, three (2%) were from other
countries of Europe, two (1%) from Nigeria, and one (1%)
from Brazil. All participants were white, except for the two
Nigerians, who were black. No patient had missing data.
Tables 1 and 2 summarise the study results. The overall
mean homocysteine serum level was 11.9 µmol/L (medi-
an: 10.6 µmol/L, interquartile range: 8.4–13.5 µmol/L, and
minimum to maximum range: 4.1–39.9 µmol/L). A total
of 54 patients (37%) presented with homocysteine serum
levels higher than the upper limit of normal. The mean
homocysteine serum level in patients with parenteral HIV
risk behaviour was 11.5 µmol/L, and in those with sexual
HIV risk behaviour it was 12.3 µmol/L (P = 0.037). The
mean homocysteine serum level in patients without hep-
atitis C virus co-infection was 11.5 µmol/L, and in those
with hepatitis C virus co-infection it was 12.1 µmol/L (P
= 0.042). A total of 31 patients (21%) were taking tri-
methoprim/sulfamethoxazole. The mean homocysteine ser-
um level was 12.1 µmol/L in those patients, as compared
to 11.8 in those who were not taking the medication (P =
0.793). We excluded two patients from the study because
they were taking vitamin supplements.
Overall 117 patients (81%) were receiving antiretroviral
medication. CD4 cell count was higher than 200 cells per
mm3 in 114 participants (79%), and HIV RNA was lower
than 1000 copies/ml (3.0 log10) in 115 participants (79%).
A total of three of our patients (2%) had suffered a major
cardiovascular event previously, two aged 70 and 71 re-
spectively had a myocardial infarction. They were the two
oldest patients in the study. The other patient with an ante-
cedent of cardiovascular disease presented with an extens-
ive ischaemic stroke at the age of 37. All 23 patients with
a dyslipidaemia were on lipid-reducing medication. All 24
patients with diabetes mellitus were on treatment with in-
sulin and/or oral antidiabetic drugs. And 15 of the 17 pa-
tients with hypertension were on blood pressure lowering
medication. The remaining two patients with hypertension
were on treatment with low salt diet.
Of the 89 patients with hepatitis C virus co-infection, 81
(91%) had parenteral HIV risk behaviour pattern and 8
(9%) a sexual risk behaviour pattern.
Multiple regression
A standard multiple linear regression was performed
between homocysteine serum level as the dependent vari-
able and a history of cardiovascular disease, family history
of early coronary disease, HIV risk behaviour, hepatitis C
virus co-infection, height, systolic blood pressure, diastolic
blood pressure, total cholesterol, measured LDL-cholester-
ol, folic acid, and vitamin B12 serum levels as independent
variables.
The other study variables were excluded from the model
for the following reasons: A) age, gender, anti-retroviral
treatment, history of diabetes mellitus, history of hyper-
tension, history of dyslipidaemia, alcohol abuse, weight,
body mass index, waist circumference, “HeartScore”, CD4
lymphocyte count, glucose, HDL-cholesterol, triglyceride,
glycosylated haemoglobin, and C-reactive protein because
of lack of relationship with homocysteine serum level; B)
hip circumference and waist to hip ratio, because they were
highly correlated with other included variables; and C) cur-
rent smoker, HIV RNA detectable and fibrinogen after ap-
plication of the best subsets procedure.
The regression model was significantly different from zero:
F = 5.98, P <0.001. Adjusted R2 was = 27.6% and Mallows
C-p was = 12.2. Table 3 displays detailed information re-
garding regression coefficients of independent variables.
The analysis of standardised residuals showed that they had
a normal distribution with mean zero, they had approxim-
ately the same variance for each predicted value of homo-
cysteine serum levels, and they were independent from
each other.
A total of seven independent variables contributed signi-
ficantly to prediction of homocysteine serum level as log-
arithmically transformed: family history of early coron-
ary disease, sexual (versus parenteral) HIV risk behaviour,
hepatitis C virus co-infection, height, folic acid and vitamin
B12.
Discussion
Serum level of homocysteine was higher than normal in
37% of our patients. Other studies carried out in HIV in-
fected patients have found lower rates of this abnormality
[17–20] and studies performed in other populations have
shown great variability in the prevalence of the condition
[14, 21–24].
Table 2: Blood analysis results of the study patients.
HIV RNA detectable *, patients (%) 63 (43)
CD4 lymphocyte count, per mm3, mean (± SD) 510 (± 380)
Glucose, mg/dL, mean (± SD) 105 (± 31)
Total cholesterol, mg/dL, mean (± SD) 174 (± 47)
HDL-cholesterol, mg/dL, mean (± SD) 41.2 (± 13.1)
Measured LDL-cholesterol, mg/dL, mean (± SD) 110 (± 36)
Triglyceride, mg/dL, mean (± SD) 154 (± 113)
Glycosylated haemoglobin, %, mean (± SD) 5.67 (± 0.98)
Fibrinogen, mg/dL, mean (± SD) 369 (± 113)
C-reactive protein, mg/dL, median (interquartile range) 3.33 (1.94 – 6.42)
Folic acid, µg/L, mean (± SD) 5.91 (± 5.37)
Vitamin B12, ng/L, mean (± SD) 375 (± 200)
Homocysteine, µmol/L, mean (± SD) 11.9 (± 5.9)
* Limit of detection: 20 copies/ml
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The patients in our study were predominantly males in their
fourth or fifth decade of life who had been parenterally in-
fected with HIV. A majority of them were co-infected with
hepatitis C virus. Similar epidemiological characteristics of
HIV infected people have previously been found in our
community and many other regions of Spain [25]. Most of
our patients were on anti-retroviral medication, and HIV
infection was acceptably controlled in a large number of
them.
In our patients there was an increased prevalence of some
cardiovascular risk factors. The high prevalence of the
habit of smoking, present in 74% of participants, was espe-
cially relevant. This percentage was probably so high be-
cause most were intravenous drug users. Nonetheless, the
figure is considerably greater than that observed in most
other populations [26], and denotes the urgent necessity of
specific programmes directed at diminishing the addiction
in our community. Despite this, the calculated 10-year risk
of suffering a cardiovascular disease, as estimated by the
“HeartScore” equation, was, in general, low among our pa-
tients. This was presumably due to the acceptable serum
levels of total cholesterol and the relatively young age of
the majority of participants [27].
The association of increased serum homocysteine levels
with increased serum folic acid and vitamin B12 levels is
already well known [6, 7]. Therefore, the most relevant
finding in our study was the association of high homo-
cysteine serum levels with hepatitis C virus infection and
with sexual (versus parenteral) HIV risk behaviour. Never-
theless, it must be noted that the differences in homo-
cysteine serum levels were small between hepatitis C virus
infected and non-infected patients, and between patients
with sexual or parenteral HIV risk behaviour. Previous
studies on HIV-infected patients did not find such asso-
ciations, although only univariate analyses were carried
out when the possible relationship of homocysteine serum
level with those variables was evaluated [17, 19]. Our res-
ults emphasise the importance of performing multivariate
analyses to correctly assess possible associations of this
kind as they are much more reliable than univariate ana-
lyses.
In a review of the literature, we have found only two stud-
ies assessing the possible relationship between increased
homocysteine serum level and hepatitis C virus infection
in the general population. In one study, an association was
found between the two variables in a univariate analysis,
but not in a multivariate one [28]. In the second study,
which included only a small group of subjects, no relation-
ship was found in a univariate analysis [29].
We did not find a plausible explanation for the difference
in homocysteine serum level between patients with sexual
or parenteral HIV risk behaviour. Hopefully other studies
in the future will help in understanding this result.
Interestingly high homocysteine serum level has been
found to be associated with increased risk of liver fibrosis
progression [30–32] and with a lower rate of sustained vir-
ological response to pegylated-interferon alpha2b plus rib-
avirin therapy, in patients with chronic hepatitis C [33].
Our study also showed an association of high homo-
cysteine serum levels with the presence of a family history
of early coronary disease, high diastolic blood pressure and
low serum levels of folic acid and Vitamin B12. All these
associations had been well documented previously in HIV-
infected patients [20, 34, 35] and in the general population
[6]. Our results, however, emphasise once more the well es-
tablished association of increased homocysteine level with
cardiovascular risk factors.
Height was also found to be associated with high homo-
cysteine serum level among our patients. However, the re-
gression coefficient was very small, which probably im-
plies a mild influence of the variable on the amino acid
level. It is also possible that this is merely a chance result.
In contrast with other studies carried out in HIV-infected
patients [19, 34, 36], we did not find an association
between advanced age and higher homocysteine serum
levels. Other cardiovascular risk factors, such as waist cir-
cumference or dyslipidaemia, previously found to be re-
lated to homocysteine serum level, did not show a signi-
ficant association with homocysteine serum levels in our
study. This was probably due to the relatively small number
of patients in our study. Although it is also important to
take into account that many of the associations found by
other authors are based on univariate analysis. For this
reason they must be interpreted with care [17].
We found no association between antiretroviral treatment
with high homocysteine serum levels. Some other authors
have found such an association, although again with uni-
variate analysis [18], whilst others have not [17, 34, 36].
Moreover we found no association of advanced HIV in-
fection with homocysteine serum level. This also implied
Table 3: Information regarding the coefficients of the independent variables of the multiple regression model*.
Independent variable Coefficient SE T P
Constant 0.0471 0.2662 0.18 0.860
History of cardiovascular disease 0.1712 0.0881 1.94 0.054
Family history of early coronary disease 0.0751 0.0337 2.23 0.027
Sexual HIV risk behaviour 0.1004 0.0410 2.45 0.016
Hepatitis C virus co-infection 0.1272 0.0410 3.10 0.002
Height, cm 0.0045 0.0014 3.10 0.002
Blood pressure systolic, mm Hg –0.0013 0.0009 –1.45 0.149
Blood pressure diastolic, mm Hg 0.0026 0.0013 1.99 0.049
Total cholesterol, mg/dL 0.0014 0.0008 1.67 0.097
Measured LDL-cholesterol, mg/dL –0.0014 0.0010 –1.35 0.180
Folic acid, µg/L –0.0094 0.0027 –3.79 <0.001
Vitamin B12, ng/L –0.0002 0.0001 –2.98 0.003
* Dependent variable: homocysteine serum level, µmol/L; SE denotes standard error; T denotes t test; P denotes significance level.
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an unlikely association between trimethoprim/sulfameth-
oxazole and homocysteine serum level among our patients.
Other authors have found a similar result [18, 37].
Despite including several well known determinants of
homocysteine serum level, our multivariate model only ex-
plained 27.6% of the variability of the amino acid. Other
similarly designed studies have shown comparable findings
[17]. This means that knowledge of the determinants of ser-
um levels of homocysteine is still very limited and more
studies are needed to clarify the real relationship of the
amino acid to cardiovascular risk factors.
The main limitations of the present study are its cross-sec-
tional design and the relatively small population analysed.
Failure to include other variables that may influence homo-
cysteine serum level [14, 35] is another potential prob-
lem. Despite those reservations, our study provides some
new information regarding the association of homocysteine
with cardiovascular risk factors and other conditions in the
HIV-infected population. Our results cannot be generalised
to the rest of the population, as clinical presentation of dis-
eases and response to treatments are not always the same in
the HIV and the general population [38].
In brief, our results show that homocysteine serum level
was higher than normal in 37 % of patients and we found
an association between higher homocysteine serum level
and HIV sexual risk behaviour and hepatitis C virus co-in-
fection.
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